Loading...
Market
What will be Wainzua's market share in the EU by the end of 2025?
2
Resolution / Starting Odds
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%
Market analysis reports from reputable sources like IMS Health or company financial disclosures
Story
CHMP Recommends Approval of Ionis and AstraZeneca's Wainzua for Rare Polyneuropathy
Oct 21, 2024, 06:10 AM
The Committee for Medicinal Products for Human Use (CHMP) in the EU has recommended the approval of Wainzua (eplontersen), a treatment developed by Ionis Pharmaceuticals and AstraZeneca, for adult patients with stage 1 or stage 2 polyneuropathy associated with hereditary transthyretin-mediated amyloidosis. This recommendation marks a significant step forward for patients suffering from this rare condition.
View original story
Similar markets
Increase by more than 5% • 25%
Increase by 0-5% • 25%
No change • 25%
Decrease • 25%
Low (<10%) • 25%
Moderate (10-30%) • 25%
High (30-50%) • 25%
Very High (>50%) • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Increase • 25%
Decrease • 25%
Remain the same • 25%
Other • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 5% • 25%
5% to 10% • 25%
10% to 15% • 25%
More than 15% • 25%
Below 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
Above 30% • 25%
Less than 10% • 25%
10% to 25% • 25%
25% to 50% • 25%
More than 50% • 25%
Increase by more than 5% • 25%
Increase by 1-5% • 25%
No significant change • 25%
Decrease • 25%